The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

医学 强的松 硫唑嘌呤 格雷夫斯病 累积剂量 内科学 甲基强的松龙 养生 泼尼松龙 胃肠病学 外科 儿科 甲状腺 疾病
作者
Luigi Bartalena,George Jean Kahaly,L. Baldeschi,Colin Mark Dayan,Anja Katrin Eckstein,C Marcocci,Michele Marinò,Bijay Vaidya,Wilmar M. Wiersinga,_ _,_ _,Göksün Ayvaz,Onur Konuk,Jasmina Ćirić,Bijliana Beleslin,Antonella Boschi,Maria Cristina Burlacu,Dan Morris,Rosario Le Moli,Antonio Marino
出处
期刊:European journal of endocrinology [Oxford University Press]
卷期号:185 (4): G43-G67 被引量:1074
标识
DOI:10.1530/eje-21-0479
摘要

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia. In mild and active GO, control of risk factors, local treatments, and selenium (selenium-deficient areas) are usually sufficient; if RAI treatment is selected to manage GD, low-dose oral prednisone prophylaxis is needed, especially if risk factors coexist. For both active moderate-to-severe and sight-threatening GO, antithyroid drugs are preferred when managing Graves' hyperthyroidism. In moderate-to-severe and active GO i.v. glucocorticoids are more effective and better tolerated than oral glucocorticoids. Based on current evidence and efficacy/safety profile, costs and reimbursement, drug availability, long-term effectiveness, and patient choice after extensive counseling, a combination of i.v. methylprednisolone and mycophenolate sodium is recommended as first-line treatment. A cumulative dose of 4.5 g of i.v. methylprednisolone in 12 weekly infusions is the optimal regimen. Alternatively, higher cumulative doses not exceeding 8 g can be used as monotherapy in most severe cases and constant/inconstant diplopia. Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, (b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; (c) orbital radiotherapy combined with oral or i.v. glucocorticoids, (d) teprotumumab; (e) rituximab and (f) tocilizumab. Sight-threatening GO is treated with several high single doses of i.v. methylprednisolone per week and, if unresponsive, with urgent orbital decompression. Rehabilitative surgery (orbital decompression, squint, and eyelid surgery) is indicated for inactive residual GO manifestations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
兮兮发布了新的文献求助10
1秒前
lmn发布了新的文献求助30
1秒前
1秒前
田様的应助被pp009900采纳,获得10
1秒前
陈雯完成签到 ,获得积分10
2秒前
3秒前
liubin0901发布了新的文献求助10
4秒前
Clarissa发布了新的文献求助10
4秒前
4秒前
Chinno完成签到,获得积分10
4秒前
轻松念之发布了新的文献求助10
4秒前
hope完成签到 ,获得积分10
4秒前
寸愿完成签到,获得积分10
4秒前
蓝天0810完成签到,获得积分10
5秒前
可靠盼旋发布了新的文献求助20
5秒前
完美世界的应助被赤壁采纳,获得10
6秒前
小蘑菇的应助被路宇鹏采纳,获得10
6秒前
科研通AI6.4的应助被曲奇饼干采纳,获得10
7秒前
mmm完成签到,获得积分10
7秒前
chenisyu完成签到,获得积分10
7秒前
7秒前
7秒前
Jasper的应助被wsf2023采纳,获得10
8秒前
所所的应助被好好好采纳,获得10
9秒前
玛卡巴卡完成签到,获得积分20
9秒前
香蕉觅云的应助被呆萌绿海采纳,获得10
10秒前
10秒前
xingxing完成签到,获得积分10
11秒前
jiajia发布了新的文献求助10
11秒前
Orange的应助被郑石采纳,获得10
12秒前
12秒前
不语完成签到,获得积分10
13秒前
英姑的应助被科研通管家采纳,获得10
13秒前
初景的应助被科研通管家采纳,获得20
14秒前
英俊的铭的应助被科研通管家采纳,获得10
14秒前
Ava的应助被梦酱采纳,获得10
14秒前
14秒前
慕青的应助被科研通管家采纳,获得10
14秒前
大胆蛋挞发布了新的文献求助10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178375
求助须知:如何正确求助?哪些是违规求助? 9569182
关于积分的说明 21802781
捐赠科研通 7773247
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556793
邀请新用户注册赠送积分活动 2478346